 |
市場調査レポート
世界の前立腺癌診断および治療市場：種類、診断法、治療法、地域別 - 成長、動向、予測（2018年〜2023年）Global Prostate Cancer Diagnostics & Therapy Market - Segmented by Type, Diagnosis, Treatment, and Geography - Growth, Trends, and Forecast (2018 - 2023) |
||||||
| 発行 | Mordor Intelligence LLP | 商品コード | 660546 | ||||
| 出版日 | ページ情報 | 英文 112 Pages 納期: 即日から翌営業日 |
|||||
| 価格 |
|
||||||
| 世界の前立腺癌診断および治療市場：種類、診断法、治療法、地域別 - 成長、動向、予測（2018年〜2023年） Global Prostate Cancer Diagnostics & Therapy Market - Segmented by Type, Diagnosis, Treatment, and Geography - Growth, Trends, and Forecast (2018 - 2023) | ||
| 出版日: 2018年05月01日 | ページ情報: 英文 112 Pages |
|
世界の前立腺癌診断および治療市場は、2018年から2023年にかけて6.1%のCAGRで推移することが予測されています。2016年においては、収益ベースで最大のシェアを占めた北米地域が市場を牽引しました。
当レポートでは、世界の前立腺癌診断および治療市場を調査し、市場の概要、タイプ・診断法・治療法・地域別の市場規模の推移と予測、市場動向、成長要因・阻害要因ならびに市場機会・課題の分析、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。
The prostate cancer diagnostics market is expected to witness a CAGR of 6.1% during the forecast period (2018-2023). North America was leading the global market with the largest revenue share in 2016.
The high prevalence rate of prostate cancer is a key factor, which is driving the global market for the prostate cancer. Prostate cancer is the second-leading cause of death in the United States. According to National Cancer Institute, it is estimated that there were around 161,360 new cases of prostate cancer and an estimated 26,730 people will die due to it. Based on these statistics, we can see that the prevalence rate of prostate cancer is increasing across the world and hence, it is driving the market.
The other factors include innovation in drugs and developments in genomics and proteomics, rise in the funding in both public and private sectors, in the field of drug development, technological advancement in oncology diagnostics and therapeutics area.
There are many new drugs that have increased the life expectancy of prostate cancer patients and have been approved by the Food & Drug Administration. But these drugs are having a high cost, which is a threat for the patients and the insurers, both. These expensive drugs are not being paid by the insurance companies and the reimbursement level for them is very low. Hence, only few people are capable of affording these drugs. Therefore, because of this high cost, the use of generic drugs is more, and hence, it is hindering the growth of the prostate cancer drugs market.
The other factors include, low success rate of clinical trials and side effects of the treatments.
North America is the leading global market with the largest revenue share in 2016. Due to the rising prevalence of the diseases and high mortality rate of the prostate cancer in the United States, North America is dominating the market. Asia-Pacific is also projected to be the fastest growing region, due to the improving healthcare infrastructure and the growing investments by the key market players.
February 2017: AstraZeneca entered into an agreement with TerSera Therapeutics LLC, for Zoladex in the United States and Canada. Zoladex is an injectable luteinising hormone-releasing agonist, which is used to treat prostate cancer, breast cancer, and certain benign gynaecological disorders.
Major Players: ABBOTT, ASTRAZENECA, ASTELLAS PHARMA INC., BAYER AG, BIOMARK DIAGNOSTICS INC., SANOFI, IPSEN, TOLMAR PHARMACEUTICALS INC., INDEVUS PHARMACEUTICALS INC., DENDREON INC., FERRING BV, AND CELLANYX LLC amongst others.
Current and future market outlook for prostate cancer diagnostics, in the developed and emerging markets
Analyze various perspectives on the market, with the help of Porter's five forces analysis
The segment that is expected to dominate the market
Regions that are expected to witness the fastest growth during the forecast period
Identify the latest developments, market shares, and strategies employed by the major market players
3 months analyst support, along with the market estimate sheet (in Excel)
This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.
